TMDX

Over the past six months (April-October 2026), TransMedics Group, Inc. (TMDX) stock declined approximately 29.19%, with the share price at $82.73 on September 28, 2026. Key events included Q1 2026 earnings on May 5, 2026, reporting $173.9 million in revenue (up 21% year-over-year) and $7.3 million in net income, while reiterating 2026 revenue guidance. Q2 2026 earnings on August 4, 2026, showed $189.9 million in revenue (up 21% year-over-year), driven by increased OCS utilization, though net income fell to $14.7 million due to increased operating expenses. The company completed a strategic investment in PAD Aviation on July 1, 2026, to establish a European air logistics network, appointed Fernando Araujo as CFO on September 10, 2026, and reaffirmed its full-year 2026 revenue outlook. Management participated in investor conferences in September 2026, and in early October 2026, a major global bank and Barclays initiated 'overweight' coverage. Insider trading over the past 12 months showed net selling of $3.8 million, with one director purchasing $109,000 of stock.